Reading between the lines: direct-to-consumer advertising of genetic testing in the USA

Area of Science:

• Biotechnology
• Medical Ethics
• Genetics

Background:

• Direct-to-consumer (DTC) marketing for genetic tests is increasing as these tests integrate into clinical practice.
• Advertisements for genetic mutation tests, such as those for BRCA1 and BRCA2, target consumers directly.
• These tests can indicate a higher risk for hereditary cancers like breast and ovarian cancer.

Purpose of the Study:

• To critique a specific biotechnology company's advertisement for a commercial BRCA1/BRCA2 genetic mutation test.
• To analyze the advertisement's ethical implications and potential to mislead consumers.
• To raise awareness about the need for critical evaluation of DTC genetic testing marketing.

Main Methods:

• Content analysis of a print advertisement found in a theatre playbill.
• Evaluation of the advertisement's claims regarding BRCA1 and BRCA2 genetic mutations.
• Assessment of the advertisement's target audience and marketing strategy.

Main Results:

• The advertisement targets a vulnerable audience, leveraging emotional content from a play about ovarian cancer.
• The promotional material provides incomplete and inaccurate information about the genetic test.
• The ad improperly directs consumers to contact the company directly, bypassing healthcare providers.

Conclusions:

• The analyzed advertisement exemplifies problematic direct-to-consumer marketing of genetic tests.
• Consumers are misguided towards direct engagement with the company instead of consulting healthcare professionals for personalized risk assessment.
• Increased vigilance is necessary to counter potentially misleading commercial genetic testing advertisements in the evolving healthcare landscape.